



To NASDAQ OMX Copenhagen A/S  
Announcement no. 20-14 / Copenhagen, July 31, 2014

**Topotarget A/S**  
Symbion  
Fruebjergvej 3  
DK-2100 Copenhagen  
Denmark  
T: +45 39178392  
E: [enquiries@topotarget.com](mailto:enquiries@topotarget.com)  
Comp reg.: 2569 5771  
[www.topotarget.com](http://www.topotarget.com)

## Share capital and voting rights at July 31, 2014

In accordance with Executive Order no. 657 of June 22, 2012 concerning Issuers' Disclosure Obligations, it is hereby notified that on July 31, 2014, Topotarget A/S had a share capital of nominal DKK 145,791,112, consisting of 145,791,112 shares each of DKK 1 nominal value. Each share of DKK 1 carries one vote, corresponding to a total number of voting rights of 145,791,112.

Please note that today is the last trading day for the shares of Topotarget A/S as a result of the merger with Onxeo SA (BioAlliance Pharma SA). The shares in the continuing company will be admitted to trading and official listing on NASDAQ OMX Copenhagen from tomorrow, August 1, 2014.

### Topotarget A/S

For further information, please contact:

Anders Vadsholt, CEO – direct: +45 39178345

### Background information

#### About Topotarget

Topotarget (NASDAQ OMX: TOPO) is a Danish-based biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to the clinical development and registration of oncology products. In collaboration with Spectrum Pharmaceuticals, Inc., Topotarget focuses on the development of its lead drug candidate, belinostat, which has shown positive results in the treatment of hematological malignancies and solid tumors, obtained by both mono- and combination therapy. For more information, please refer to [www.topotarget.com](http://www.topotarget.com).

#### Topotarget Safe Harbor Statement

This announcement may contain forward-looking statements, including statements about Topotarget A/S' expectations to the progression of Topotarget A/S' clinical pipeline and with respect to cash burn guidance. Such statements are subject to risks and uncertainties of which many are outside the control of Topotarget A/S, and which could cause actual results to differ materially from those described. Topotarget A/S disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by Danish law.